The NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

A new approach to cancer treatment became available shortly before Jimmy Carter needed it. Now it's a pillar of care.

During a Case-Based Roundtable® event, Laahn Foster, MD, discussed the 2024 update to the RELATIVITY-047 trial in advanced ...

For patients with advanced melanoma, there is a survival benefit for nivolumab plus ipilimumab and for nivolumab monotherapy ...

Nivolumab, given with or without ipilimumab, showed durable 10-year survival outcomes in patients with advanced melanoma.

A phase 2 trial of ipilimumab plus nivolumab has met its primary end point of 12-month overall survival rate in non-clear ...

For patients with resectable non-small-cell lung cancer (NSCLC), perioperative nivolumab is associated with event-free ...

A phase 2 trial investigated the efficacy and safety of nivolumab/ipilimumab in molecularly selected patients with mCRPC, including those with a mismatch repair deficient, high tumor mutational burden ...

A huge leap in fine for wrongly using mobility parks, help with childcare costs and access to Keytruda are just some of the ...

Nivolumab plus ipilimumab can provide long-term benefits to patients with advanced melanoma, according to a 10-year update of the CheckMate 067 trial.

Researchers compared health-related quality of life with nivolumab added to first-line chemo vs chemo alone in patients with ...